SK150298A3 - Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system - Google Patents

Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system Download PDF

Info

Publication number
SK150298A3
SK150298A3 SK1502-98A SK150298A SK150298A3 SK 150298 A3 SK150298 A3 SK 150298A3 SK 150298 A SK150298 A SK 150298A SK 150298 A3 SK150298 A3 SK 150298A3
Authority
SK
Slovakia
Prior art keywords
antibody
seq
sequence
human
light chain
Prior art date
Application number
SK1502-98A
Other languages
English (en)
Slovak (sk)
Inventor
Clive G Copley
Michael D Edge
Stephen C Emery
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9609405.7A external-priority patent/GB9609405D0/en
Priority claimed from GBGB9703103.3A external-priority patent/GB9703103D0/en
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of SK150298A3 publication Critical patent/SK150298A3/sk

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
SK1502-98A 1996-05-04 1997-04-29 Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system SK150298A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9609405.7A GB9609405D0 (en) 1996-05-04 1996-05-04 Protein
GBGB9703103.3A GB9703103D0 (en) 1997-02-14 1997-02-14 Protein
PCT/GB1997/001165 WO1997042329A1 (en) 1996-05-04 1997-04-29 Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system

Publications (1)

Publication Number Publication Date
SK150298A3 true SK150298A3 (en) 1999-04-13

Family

ID=26309272

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1502-98A SK150298A3 (en) 1996-05-04 1997-04-29 Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system

Country Status (19)

Country Link
US (2) US6277599B1 (zh)
EP (1) EP0896626B1 (zh)
JP (1) JP2000510692A (zh)
CN (1) CN1217750A (zh)
AT (1) ATE350478T1 (zh)
AU (1) AU719513B2 (zh)
BR (1) BR9708910A (zh)
CA (1) CA2250579A1 (zh)
CZ (1) CZ353698A3 (zh)
DE (1) DE69737188T2 (zh)
ES (1) ES2279539T3 (zh)
HU (1) HUP9901562A3 (zh)
IL (1) IL126772A0 (zh)
NO (1) NO985120L (zh)
NZ (1) NZ331978A (zh)
PL (1) PL329871A1 (zh)
SK (1) SK150298A3 (zh)
TR (1) TR199802227T2 (zh)
WO (1) WO1997042329A1 (zh)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL329871A1 (en) * 1996-05-04 1999-04-12 Zeneca Ltd Monoclonal antibody agains cea, coniugates incorporating that antibody and their therapeutic application in the adept system
AU6000698A (en) * 1997-02-14 1998-09-08 Zeneca Limited Proteins
GB9709421D0 (en) * 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
JP2002504372A (ja) * 1998-02-25 2002-02-12 ザ ダウ ケミカル カンパニー 高親和性ヒト型化抗−ｃｅａモノクロ−ナル抗体
WO2000029583A2 (en) * 1998-11-19 2000-05-25 Incyte Pharmaceuticals, Inc. Immunoglobulin superfamily proteins
JP2003515323A (ja) * 1999-11-18 2003-05-07 オックスフォード バイオメディカ（ユーケイ）リミテッド 抗 体
GB2371803A (en) * 1999-11-18 2002-08-07 Oxford Biomedica Ltd Antibodies
AU2001262216A1 (en) * 2000-04-22 2001-11-07 Stefan Barth Apoptotic agents
GB0210783D0 (en) * 2002-05-10 2002-06-19 Polonelli Luciano Anti-microbial polypeptides
KR100604037B1 (ko) * 2002-08-02 2006-07-24 주식회사유한양행 항체 경쇄 카파 발현벡터
US20050008618A1 (en) * 2003-02-27 2005-01-13 Howard Kaufman Composition for delivering an agent to a target cell and uses thereof
AU2004217433A1 (en) * 2003-03-04 2004-09-16 Alexion Pharmaceuticals, Inc. Vectors used to create hybrid constant regions
ATE517920T1 (de) * 2003-04-23 2011-08-15 Medarex Inc Humanisierte antikörper gegen interferon-alpha- rezeptor-1 (ifnar-1)
EP1691763A4 (en) * 2003-12-12 2008-03-12 Genencor Int CAB MOLECULES
JP4805848B2 (ja) * 2004-02-12 2011-11-02 モルフォテック、インク． 腫瘍抗原の生物活性を特異的に阻止するモノクローナル抗体
DE602005023138D1 (de) * 2004-04-15 2010-10-07 Genencor Int Anti-cea scfv-beta-lactamase konstrukte (cab moleküle) in adept
CA2585776A1 (en) 2004-10-29 2006-05-11 University Of Southern California Combination cancer immunotherapy with co-stimulatory molecules
US7592426B2 (en) 2005-03-10 2009-09-22 Morphotek, Inc. Anti-mesothelin antibodies
EP1879922A2 (en) 2005-04-22 2008-01-23 Morphotek, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
BRPI0616359B8 (pt) 2005-09-30 2022-08-30 Medimmune Ltd Composição farmacêutica, processo para purificação de um anticorpo de il-13 e uso de uma composição farmacêutica contendo um anticorpo
WO2008011157A2 (en) 2006-07-20 2008-01-24 The General Hospital Corporation Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting
US8043830B2 (en) * 2008-02-01 2011-10-25 The Regents Of The University Of California Biotin-ligase system for secretion of biotinylated protein
CN101607985B (zh) * 2008-12-24 2013-03-27 中国科学院生物物理研究所 抗人cea的单克隆抗体，包含其的组合物，及其用途
CN101704892B (zh) * 2009-12-09 2014-02-12 中国人民解放军军事医学科学院生物工程研究所 一种抗uPAR人源化抗体及其编码基因与应用
KR20130028055A (ko) 2010-01-28 2013-03-18 글락소 그룹 리미티드 Ｃｄ １２７ 결합 단백질
US8846042B2 (en) 2011-05-16 2014-09-30 Fabion Pharmaceuticals, Inc. Multi-specific FAB fusion proteins and methods of use
KR102037541B1 (ko) 2011-10-28 2019-10-29 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 폴리펩티드 구축물 및 이의 용도
CN102526707B (zh) * 2012-01-13 2015-04-22 成都博发生物技术有限公司 共刺激因子及融合蛋白的新用途
RU2493166C1 (ru) * 2012-04-09 2013-09-20 Общество с ограниченной ответственностью "Технофарма" Наноантитело, специфически связывающее белок сеа, способ его использования для детекции этого белка
CN102838676A (zh) * 2012-09-26 2012-12-26 李彬 一种癌胚抗原单抗及包含该抗体的芯片以及应用
RS53818B1 (en) 2012-10-12 2015-06-30 Spirogen Sàrl PIROLOBENZODIAZEPINI I NJIHOVI conjugated
CA2905181C (en) 2013-03-13 2020-06-02 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
EA033115B1 (ru) 2013-04-29 2019-08-30 Тева Фармасьютикалз Острэйлиа Пти Лтд. АНТИТЕЛА ПРОТИВ CD38 И СЛИТЫЕ БЕЛКИ С ОСЛАБЛЕННЫМ ИНТЕРФЕРОНОМ АЛЬФА-2b
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
WO2016037644A1 (en) 2014-09-10 2016-03-17 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
IL251822B2 (en) 2014-10-29 2023-03-01 Teva Pharmaceuticals Australia Pty Ltd Variants of interferon alpha-2-b
JP7034489B2 (ja) 2016-03-15 2022-03-14 アイタブメッド （エイチケイ） リミテッド 多重特異性Ｆａｂ融合タンパクおよびその使用
US11618784B2 (en) 2016-07-19 2023-04-04 Teva Pharmaceuticals Australia Pty Ltd. Anti-CD47 combination therapy
WO2018069289A1 (en) 2016-10-11 2018-04-19 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
CN106749667B (zh) * 2016-12-04 2020-07-14 深圳市国创纳米抗体技术有限公司 一种抗癌胚抗原的纳米抗体及其应用
WO2019224275A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
US20210128617A1 (en) * 2019-08-27 2021-05-06 The Trustees Of The University Of Pennsylvania SYNTHETIC CARS TO TREAT IL13R-alpha-2 POSITIVE HUMAN AND CANINE TUMORS
WO2022079211A1 (en) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8809616D0 (en) 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
CA2161351C (en) * 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
GB9324807D0 (en) 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
PL329871A1 (en) * 1996-05-04 1999-04-12 Zeneca Ltd Monoclonal antibody agains cea, coniugates incorporating that antibody and their therapeutic application in the adept system

Also Published As

Publication number Publication date
WO1997042329A1 (en) 1997-11-13
TR199802227T2 (xx) 2000-07-21
US6277599B1 (en) 2001-08-21
EP0896626B1 (en) 2007-01-03
US20020142359A1 (en) 2002-10-03
EP0896626A1 (en) 1999-02-17
IL126772A0 (en) 1999-08-17
NO985120D0 (no) 1998-11-03
CA2250579A1 (en) 1997-11-13
CZ353698A3 (cs) 1999-02-17
CN1217750A (zh) 1999-05-26
DE69737188D1 (de) 2007-02-15
HUP9901562A3 (en) 2000-06-28
AU719513B2 (en) 2000-05-11
PL329871A1 (en) 1999-04-12
DE69737188T2 (de) 2007-10-11
NZ331978A (en) 2000-05-26
AU2645597A (en) 1997-11-26
ATE350478T1 (de) 2007-01-15
ES2279539T3 (es) 2007-08-16
US6903203B2 (en) 2005-06-07
HUP9901562A2 (hu) 1999-08-30
BR9708910A (pt) 1999-08-03
NO985120L (no) 1998-12-29
JP2000510692A (ja) 2000-08-22

Similar Documents

Publication Publication Date Title
AU719513B2 (en) Monoclonal antibody to CEA, conjugates comprising said antibody, and their therapeutic use in an adept system
AU709503B2 (en) Delivery system using mAb 3E10 and mutants and/or functional fragments thereof
CA2019559C (en) Bispecific and oligospecific mono- and oligovalent receptors, the preparation and use thereof
JP5981688B2 (ja) ヒトインスリン受容体を介する医薬品の送達
JP5719596B2 (ja) 抗体及びその誘導体
US5830478A (en) Method for delivering functional domains of diphtheria toxin to a cellular target
EP0731838B1 (en) Binding structures directed against the ca55.1 antigen
AU2004245038A1 (en) De-immunized anti-CD3 antibody
JP3805365B2 (ja) 化合物
Hoogenboom et al. Cloning and expression of a chimeric antibody directed against the human transferrin receptor.
Scallon et al. A review of antibody therapeutics and antibody-related technologies for oncology
JP5749009B2 (ja) ＥｐｈＢ４に結合するヒト化抗体を利用する癌治療剤
KR20000010771A (ko) Cea에 대한 모노클로널 항체, 이 항체를 함유하는 접합체 및adept계에서의 치료적 용도
JPH03254691A (ja) 薬剤耐性癌に対するキメラ抗体およびその製造